Ocular Therapeutix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ocular Therapeutix (OCUL).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy

11Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$22Upside to Avg. PT+204.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Needham	Serge Belanger	Maintained	Buy	$18
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$14
Oct 2, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Sep 29, 2026	Needham	Serge Belanger	Maintained	Buy	$18
Sep 16, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Sep 16, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$25
Aug 4, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$23
Jun 25, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$21→$23
Jun 18, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$21→$25
Jun 18, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$24→$30
May 6, 2026	RBC Capital	Lisa Walter	Maintained	Outperform	$30
May 5, 2026	Needham	Serge Belanger	Maintained	Buy	$18
Apr 13, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$21
Mar 3, 2026	Clear Street	Bill Maughan	PT Raise	Buy	$21→$28
Feb 20, 2026	Needham	Serge Belanger	PT Cut	Buy	$20→$18
Feb 18, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$21
Dec 9, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$21
Dec 8, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Dec 8, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$19→$21
Nov 25, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$19

Analyst Ratings News

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $25 price target.

Benzinga Newsdesk

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.

Vandana Singh

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.

Benzinga Newsdesk

Ocular Therapeutix Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

People Also Watch

People Also Watch

Ocular Therapeutix Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Ocular Therapeutix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PROUBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRONeedham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PROHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Why Is Ocular Therapeutix Stock Gaining Monday?

PROChardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

People Also Watch

People Also Watch

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

PRO
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23